VRDNViridian Therapeutics, Inc.

1. Aug 6, 2026Viridian Therapeutics Highlights Recent Business Progress and Reports Second.Earnings release · press release
2. Jun 29, 2026On June 26, 2026, the Company announced that the FDA has approved Lumvoa ™ (veligrotug-vvze) for the treatment of TED regardless of activity or duration.Regulation FD disclosure · Form 8-K
3. May 28, 2026On May 27, 2026, Viridian Therapeutics, Inc. (the “Company”) completed a voluntary prepayment of all outstanding principal, accrued and unpaid interest, fees, costs and expenses, equal to approximately $55.1 million in the aggregate (the “Payoff Amount”), under the Loan and Security Agreement, entered into and …Material agreement terminated · Form 8-K
4. May 26, 2026On May 24, 2026, Viridian Therapeutics, Inc. (the “Company”) entered into a Commercial Manufacturing Services Agreement (the “Agreement”) with WuXi Biologics (Hong Kong) Limited (“WuXi Biologics”) pursuant to which WuXi Biologics will manufacture and supply the Company’s anticipated long-term supply requirements of …Material agreement entered · Form 8-K
5. May 11, 2026On May 11, 2026, Viridian Therapeutics, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $250,000,000 aggregate principal amount of its 1.75% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the underwriters’ option to purchase up to an …Material agreement entered · Form 8-K
6. May 5, 2026Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-2 Clinical.Regulation FD disclosure · press release
7. May 5, 2026Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress.Earnings release · press release
8. Mar 30, 2026Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease.Regulation FD disclosure · press release
9. Feb 26, 2026Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
10. Nov 5, 2025Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress.Earnings release · press release
11. Oct 23, 2025On October 21, 2025, Viridian Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated (collectively, the “Representatives”) relating to the offer and sale (the …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.